SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept. 30, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced Business Combination Agreement with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding common shares of ESSA (the "Transaction"), ESSA received an amended Interim Order from the Supreme Court of British Columbia (the "Court") on September 25, 2025.

The amended Interim Order approves the previously announced date for ESSA's special meeting of the holders of common shares of the Company, optionholders and warrantholders (the "Special Meeting") of October 3, 2025, the deadline to deliver notices of dissent of

See Full Page